Dreem

Rythm, SAS, based in France, specializes in innovative digital sleep care solutions designed to improve sleep health through clinical-grade home testing and consultations with sleep specialists. Founded in 2014, Rythm, SAS operates under the brand Dreem, which focuses on developing advanced sleep care technologies. The company is headquartered in Paris, France. Rythm has successfully raised EUR 31.

00 mn in its SERIES A funding round, led by Johnson & Johnson Innovation, contributing to a total funding of EUR 31. 00 mn, resulting in a current company valuation of EUR 108. 621 mn. The founders are Anass ISSAM, Mahmoud Sleem, and Quentin De Brugière, with Cedric DeBenedetto serving as CEO.

The company has completed 7 deals, with its most recent deal occurring on July 11, 2023. Dreem Health specializes in digital sleep care solutions, primarily offering services such as video consultations with sleep specialists and at-home sleep testing. The company's core product, the Sunrise home sleep test, is clinically proven and won the SleepTech Award 2022 for its accuracy. This innovative approach allows patients to receive a high-accuracy diagnosis in real-life sleep conditions without the need for lab visits.

Dreem Health caters to a broad range of sleep disorders, including sleep apnea, insomnia, restless leg syndrome, hypersomnia, circadian rhythm disorders, and parasomnias. The company serves a diverse client base across 30+ states in the U. S. , aiming to improve sleep health for patients experiencing various sleep-related challenges, thereby enhancing their overall quality of life.

Dreem Health generates revenue through a combination of direct-to-consumer transactions and partnerships with major insurers. The transaction structure primarily involves providing services through video consultations and home sleep tests, with many insured members facing minimal out-of-pocket costs, often having a EUR 0 copay. The company offers personalized treatment plans following accurate diagnoses. Additionally, Dreem Health prescribes devices such as WatchPAT for monitoring sleep conditions, contributing to its revenue stream.

The offerings reflect a commitment to quality care, as evidenced by the high recommendation rate from patients who have utilized the services. In July 2023, Dreem was acquired by Beacon Biosignals, Inc. , a portfolio company of Casdin Capital and General Catalyst Partners, enhancing its capabilities and clinical trial operations. The acquisition aims to bolster Dreem's reach and efficacy in sleep care solutions.

Future growth will focus on expanding into additional markets and regions, potentially increasing service offerings and product lines. The recent funding will be directed toward enhancing their technical capabilities and developing new product offerings as part of their strategic expansion.